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ment with statins, suggesting a suboptimal use of resources. We
studied the drug costs associated with overtreatment and the
costs to eliminate undertreatment with statins in an elderly pop-
ulation. METHODS: Overtreatment and undertreatment with
statins were ascertained using current Dutch cholesterol man-
agement guidelines. Data were acquired from the Rotterdam
Study. This is a population-based prospective cohort study,
which started in 1990 with 7983 participants of at least 55 years
of age. This analysis focused on primary prevention of cardio-
vascular disease (CVD) excluding subjects with a history of car-
diovascular disease. To estimate patterns of medication use in
daily practice pharmacy records were obtained. RESULTS: From
the 3251 participants 464 (14%) were still alive on January 1st
2002, had no history of CVD and were undertreated. Of the 
565 participants starting statin treatment 389 (69%) were
overtreated according to the same guidelines. After projection on
the general Dutch population, the absolute costs for overtreat-
ment with statins in 2005 were estimated to be approximately
23 million Euros (Uncertainty limits (UL): 19–28 million Euro),
while the cost to eliminate undertreatment were also 23 million
Euros (UL: 19–28 million Euros). CONCLUSION: In conclu-
sion, when considering only drug costs reallocation of resources
used for statin treatment from those overtreated to those under-
treated could lead to a more efﬁcient use of resources.
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OBJECTIVES: To identify key factors determining therapeutic
decision making concerning coronary artery disease treatment in
the GPs’ and specialists’ practices. To establish role of economic
factors related. METHODS: A survey was conducted on the rep-
resentative sample of Polish physicians (184 GPs and 63 spe-
cialists in the outpatient clinics) dealing with coronary artery
disease (CAD) patients. Data were obtained with the aid of a
speciﬁc questionnaire, including 6 items completed by doctor.
RESULTS: Choosing the treatment for a CAD patient, 75% of
the GPs and specialists have taken drugs’ efﬁcacy into consider-
ation at ﬁrst. Safety of treatment (GPs 9.8% and specialists
12.7% respectively) and adherence to guidelines (9.2%; 9.5%)
were rarely considered as main factors. One third of the GPs and
specialists declared that unbearable drugs’ costs constituted the
most frequent reason for treatment discontinuation. The adverse
events (20.6% and 20.1%) and poli-therapy (20.6% and 19.6%)
were the next reasons cited. Treatment with the lowest priced
drugs (75%; 74%) and those medicines administered once a day
(75%; 71%) were described as two best ways of compliance
improvement. The most important factors leading to the change
of treatment were insufﬁcient efﬁcacy (88%) and adverse events
(81%). 70% of GPs and 74% of specialists declared, that every
third patient talked about economic issues of treatment (co-
payment, costs of diagnostic procedures and additional doctors’
consultations). Only 31.5% of the GPs and 41.3% of specialists
indicated an inﬂuence on the quality of life among the top three
most important factors determining a therapeutic decision.
CONCLUSIONS: Factors determining therapeutic decisions in
the CAD patients are quite similar among the GPs and special-
ists. Efﬁcacy and safety of therapy represented factors commonly
reported by the GPs as well as specialists. Unbearable cost of
pharmacotherapy was considered as one of the main causes
leading to treatment discontinuation and incompliance.
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OBJECTIVE: Regular testing of total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
is important for effective lipid management. Our objective was
to examine frequency of lipid testing and to assess predictors of
lipid testing frequency in UK patients newly initiated on statins
over a one year period. METHODS: This was a retrospective
cohort study performed using the UK General Practice Research
Database. Patients aged ≥35 years were included if they received
their ﬁrst ever statin between Jan-2000 and Dec-2004 and had
at least one TC, HDL-C or TG test conducted in the one year
period before statin initiation. Lipid tests performed after statin
initiation were counted until the earliest of either one-year
follow-up or statin discontinuation date plus 30 days. Poisson
regression was used to assess pre-initiation factors associated
with testing frequency for each lipid following statin initiation.
RESULTS: 57,296 patients received at least one TC, HDL-C or
TG at baseline and had one year of follow-up after statin initi-
ation. On average, patients received 1.3 ± 1.0 TC tests. However,
22.7% patients did not receive a single TC test after starting on
statins. The mean number of tests per patient for HDL-C and
TG was 0.9 ± 1.0 but 44.3% and 39.1% of patients did not
receive a single HDL-C and TG test, respectively. In the multi-
variate analysis, high cardiovascular risk [OR, 1.04; 95% CI,
1.01–1.07] and baseline TC ≥6.2 mmol/L [OR, 1.1; 95% CI,
1.06–1.18, compared with TC <5.0 mmol/L] were associated
with TC testing frequency. CONCLUSION: Higher cardiovas-
cular risk and higher baseline TC were associated with TC
testing within the ﬁrst year following statin initiation. Lack of
TC testing in approximately 2 in 10 UK patients during that
period and infrequent HDL-C and TG testing may prove as bar-
riers towards effective lipid management.
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OBJECTIVES: To develop a care map for Congestive Heart
Failure (CHF) in the UK, covering diagnosis, progression and
treatment of patients, focussing on points of interaction with the
UK NHS. METHODS: Available literature was searched for
national and local clinical guidelines and treatment algorithms
for CHF in the UK. Ten experts were consulted to validate and
complete the dataset. An interactive 1-year care map of CHF care
in the UK was then developed in MS Excel. New York Heart
Association (NYHA) bands I to IV were used to group patients
by disease severity and costs were estimated from an NHS per-
spective for 2005. Patient transition between hospital (including
readmissions), home and nursing home was modelled. Possible
surgical interventions were: heart transplantation, valve repair
and ICD. Summary statistics included: Patient disposition and
location after 1 year, total estimated costs (including where
accrued) and hospitalisation rates due to CHF. RESULTS: Over
one year, 878,000 existing CHF patients plus 63,000 new cases
would cost the NHS £896 million. The total spend (and per-
centage) on patients in hospital, at home and in nursing homes
were £550 million (62%), £298 million (33%) and £47 million
(5%) respectively. Surgery accounted for £13 million of hospital
costs. Of 941,000 CHF patients, 291,000 will be hospitalised
